Intradigm has named Samuel Zalipsky as its vice president of technology development.
Intradigm said he will be responsible for overseeing the company’s continued development of its nanoparticle-based RNAi delivery technology, as well as novel RNAi drug formulations. Salipsky will also handle Intradigm’s new technology development and in-licensing efforts.
Zalipsky has previously held positions with Alza, Sequus Pharmaceuticals, and Enzon.
Pronota, a Belgian predictive biomarker firm, has named John Berriman as its chairman.
Berriman was previously a director of Alnylam Pharmaceuticals.